Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].
ESMO Open
; 6(2): 100097, 2021 Apr.
Article
en En
| MEDLINE
| ID: mdl-33926709
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
ESMO Open
Año:
2021
Tipo del documento:
Article
País de afiliación:
Italia